相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Immune Checkpoint Inhibitors: Cardiotoxicity in Pre-clinical Models and Clinical Studies
Shirley Xu et al.
FRONTIERS IN CARDIOVASCULAR MEDICINE (2021)
The Next Decade of Immune Checkpoint Therapy
Padmanee Sharma et al.
CANCER DISCOVERY (2021)
Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609
Ahmad A. Tarhini et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Structure and Optimization of Checkpoint Inhibitors
Sarah L. Picardo et al.
CANCERS (2020)
Heart-Specific Immune Responses in an Animal Model of Autoimmune-Related Myocarditis Mitigated by an Immunoproteasome Inhibitor and Genetic Ablation
Mariella Bockstahler et al.
CIRCULATION (2020)
Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia
Joerg Herrmann
NATURE REVIEWS CARDIOLOGY (2020)
The Use of Immune Checkpoint Inhibitors in Oncology and the Occurrence of AKI: Where Do We Stand?
Rossana Franzin et al.
FRONTIERS IN IMMUNOLOGY (2020)
Checkpoint inhibitor-induced myocarditis and myasthenia gravis in a recurrent/metastatic thymic carcinoma patient: a case report
Charles Szuchan et al.
EUROPEAN HEART JOURNAL-CASE REPORTS (2020)
Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial
Yi-Long Wu et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
PubTerm: a web tool for organizing, annotating and curating genes, diseases, molecules and other concepts from PubMed records
Jose Garcia-Pelaez et al.
DATABASE-THE JOURNAL OF BIOLOGICAL DATABASES AND CURATION (2019)
Incidence of pancreatitis with the use of immune checkpoint inhibitors (ICI) in advanced cancers: A systematic review and meta-analysis
John George et al.
PANCREATOLOGY (2019)
Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study
Makoto Ueno et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2019)
Myocarditis: Uncommon but severe toxicity of immune checkpoint inhibitors
Pierre-Yves Courand et al.
BULLETIN DU CANCER (2019)
PD-L1 Prevents the Development of Autoimmune Heart Disease in Graft-versus-Host Disease
Kathryn W. Juchem et al.
JOURNAL OF IMMUNOLOGY (2018)
Cardiotoxicities associated with immune checkpoint inhibitors
Shu Yang et al.
CURRENT PROBLEMS IN CANCER (2018)
Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis
Javid J. Moslehi et al.
LANCET (2018)
Takotsubo-Like Syndrome in Cancer Patients Treated With Immune Checkpoint Inhibitors
Stephane Ederhy et al.
JACC-CARDIOVASCULAR IMAGING (2018)
Immune checkpoint inhibitors and cardiovascular toxicity
Alexander R. Lyon et al.
LANCET ONCOLOGY (2018)
Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial
Frank Stephen Hodi et al.
LANCET ONCOLOGY (2018)
Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057)
Leora Horn et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study
Matthew D. Hellmann et al.
LANCET ONCOLOGY (2017)
Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial
Michele Maio et al.
LANCET ONCOLOGY (2017)
Interstitial lung disease induced by fluoxetine: Systematic review of literature and analysis of Vigiaccess, Eudravigilance and a national pharmacovigilance database
Arianna Deidda et al.
PHARMACOLOGICAL RESEARCH (2017)
Clinical Features, Management, and Outcomes of Immune Checkpoint Inhibitor-Related Cardiotoxicity
Marion Escudier et al.
CIRCULATION (2017)
Safety and efficacy of nivolumab and standard chemotherapy drug combination in patients with advanced non-small-cell lung cancer: a four arms phase Ib study
S. Kanda et al.
ANNALS OF ONCOLOGY (2016)
Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy
Lisa Zimmer et al.
EUROPEAN JOURNAL OF CANCER (2016)
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
Roy S. Herbst et al.
LANCET (2016)
Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial
F. Stephen Hodi et al.
LANCET ONCOLOGY (2016)
Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial
Scott J. Antonia et al.
LANCET ONCOLOGY (2016)
Fulminant Myocarditis with Combination Immune Checkpoint Blockade
Douglas B. dbj Johnson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
R. L. Ferris et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Safety and Efficacy of Nivolumab in Patients With Metastatic Renal Cell Carcinoma Treated Beyond Progression A Subgroup Analysis of a Randomized Clinical Trial
Saby George et al.
JAMA ONCOLOGY (2016)
Meta-analysis in clinical trials revisited
Rebecca DerSimonian et al.
CONTEMPORARY CLINICAL TRIALS (2015)
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
Julie Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Julian P. T. Higgins et al.
BMJ-BRITISH MEDICAL JOURNAL (2011)
PD-1 deficiency results in the development of fatal myocarditis in MRL mice
Jian Wang et al.
INTERNATIONAL IMMUNOLOGY (2010)
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration
Alessandro Liberati et al.
BMJ-BRITISH MEDICAL JOURNAL (2009)
Programmed death ligand 1 regulates a critical checkpoint for autoimmune myocarditis and pneumonitis in MRL mice
Julie A. Lucas et al.
JOURNAL OF IMMUNOLOGY (2008)
分享论文
